Our top pick for
Low costs
Our top pick for
Education & learning
Our top pick for
Australian stocks
| 52-week range | $0.039 - $0.2 |
|---|---|
| 50-day moving average | $0.0597 |
| 200-day moving average | $0.0951 |
| Target price | $0.35 |
| PE ratio | 0 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.01 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.105
| 1 week (2023-11-21) | 10.53% |
|---|---|
| 1 month (2023-10-27) | 156.10% |
| 3 months (2023-08-29) | 66.67% |
| 6 months (2023-05-29) | -4.55% |
| 1 year (2022-11-29) | -41.67% |
|---|---|
| 2 years (2021-11-29) | -79.41% |
| 3 years (2020-11-27) | 5.00% |
| 5 years (2018-11-29) | 356.52% |
| Revenue TTM | $11.8 million |
|---|---|
| Gross profit TTM | $11.8 million |
| Return on assets TTM | -14.33% |
| Return on equity TTM | -23.1% |
| Profit margin | 0% |
| Book value | 0.03 |
| Market capitalisation | $601.9 million |
TTM: trailing 12 months
We're not expecting Imugene to pay a dividend over the next 12 months.
Imugene 's shares were split on a 1:7.5 basis on 12 November 2002. So if you had owned 7.5 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Imugene shares – just the quantity. However, indirectly, the new 650% higher share price could have impacted the market appetite for Imugene shares which in turn could have impacted Imugene 's share price.
Over the last 12 months, Imugene 's shares have ranged in value from as little as $0.039 up to $0.2. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Imugene 's is 2.543. This would suggest that Imugene 's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Looking for the best performing stocks in Australia? We update this list weekly.
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Steps to owning and managing Microsoft shares from in Australia.
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
Learn about the money market and everyday consumer money market products.
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
Follow these tips to find the best share trading platform for you.
